<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239470</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT APG01</org_study_id>
    <secondary_id>APG01</secondary_id>
    <nct_id>NCT03239470</nct_id>
  </id_info>
  <brief_title>Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Autoimmunity Centers of Excellence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho Federal Systems Division, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      T cells, a type of white blood cell called a lymphocyte, play an important role in the immune&#xD;
      system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may&#xD;
      provide protection against the development of autoimmune disease. The hope is that these&#xD;
      naturally occurring Treg cells can be utilized for the treatment of autoimmune disease and&#xD;
      potentially replace the use of chronic immunosuppressive therapies that are associated with&#xD;
      multiple side effects. There has been a small study showing safe administration of Tregs with&#xD;
      decreased disease activity in patients with insulin-dependent diabetes. Tregs are being&#xD;
      studied in lupus, cancer and organ transplantation.&#xD;
&#xD;
      This phase I trial will be conducted as an open-label, dose-escalation, multicenter trial in&#xD;
      adult participants with active pemphigus.The purpose of this study is to test the safety and&#xD;
      effect of Treg therapy in participants who have skin (cutaneous) involvement due to&#xD;
      pemphigus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 12 adults between the ages of 18 and 75 years of age who have been diagnosed with&#xD;
      pemphigus and meet all other entry criteria will be enrolled to receive one infusion of their&#xD;
      own expanded Tregs at one of the following doses:&#xD;
&#xD;
        -  1.0 x 10^8 PolyTregs or&#xD;
&#xD;
        -  2.5 x 10^8 PolyTregs.&#xD;
&#xD;
      Safety, disease activity, and mechanism of action will be assessed over a three year period,&#xD;
      using biospecimens from blood and skin. Study therapy administration will occur during an&#xD;
      overnight stay, followed by 2 weekly visits, then monthly visits from Week 8 to Week 12, then&#xD;
      quarterly visits from Week 26 to Week 52, then twice a year visits until Week 156.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Significant Events as Defined by Grade 3 or higher adverse event(s) by Week 52</measure>
    <time_frame>Baseline (Visit 0) to Week 52</time_frame>
    <description>Severity [Adverse Events (AEs) and Serious Adverse Events (SAEs)] will be reported using NCI-CTCAE grading criteria. Reference: the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 http://ctep.cancer.gov/reporting/ctc.html.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Pemphigus Foliaceus</condition>
  <condition>Pemphigus Vulgaris</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 1.0 x 10^8 PolyTregs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 2.5x10^8 PolyTregs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cohort 1: 1.0 x 10^8 PolyTregs</intervention_name>
    <description>Each participant will receive a target cell dose of 1.0 x 10^8 polyclonal Tregs.</description>
    <arm_group_label>Cohort 1: 1.0 x 10^8 PolyTregs</arm_group_label>
    <other_name>Polyclonal Regulatory T Cells</other_name>
    <other_name>autologous PolyTregs</other_name>
    <other_name>CD4+CD127lo/negCD25+ PolyTregs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cohort 2: 2.5x10^8 PolyTregs</intervention_name>
    <description>Each participant will receive a target cell dose of 2.5x10^8 polyclonal Tregs.</description>
    <arm_group_label>Cohort 2: 2.5x10^8 PolyTregs</arm_group_label>
    <other_name>Polyclonal Regulatory T Cells</other_name>
    <other_name>autologous PolyTregs</other_name>
    <other_name>CD4+CD127lo/negCD25+ PolyTregs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent;&#xD;
&#xD;
          -  Diagnosis of Pemphigus Vulgaris (PV) or Pemphigus Foliaceus (PF), defined by H&amp;E&#xD;
             staining (e.g., Haemotoxylin and Eosin) and direct immunofluorescence staining of skin&#xD;
             biopsy at any time prior to enrollment;&#xD;
&#xD;
          -  Pemphigus treated with systemic corticosteroids within the 2 years prior to screening&#xD;
             (historic or current), or treated with rituximab ≥ 12 months prior to screening;&#xD;
&#xD;
          -  Presence of:&#xD;
&#xD;
               -  anti-Dsg3 antibodies (&gt;20.0 U/ml) at screening visit consistent with diagnosis of&#xD;
                  pemphigus vulgaris or,&#xD;
&#xD;
               -  anti-Dsg1 antibodies (&gt;20.0 U/ml) at screening visit consistent with diagnosis of&#xD;
                  pemphigus foliaceus.&#xD;
&#xD;
          -  Active of PV or PF as defined by Pemphigus Disease Area Index (PDAI) overall activity&#xD;
             score 3-10 at screening visit, and PDAI overall activity score 1-12 at baseline visit;&#xD;
&#xD;
          -  Positive test for Epstein-Barr Virus (EBV) antibody;&#xD;
&#xD;
          -  Adequate venous access to support draw of 400 ml whole blood and infusion of&#xD;
             investigational therapy; and&#xD;
&#xD;
          -  An absolute Treg count of ≥ 42 cells/μL within 6 weeks prior to whole blood collection&#xD;
             at Week -2 (i.e., 2 weeks prior to planned PolyTreg Infusion).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initiation of systemic corticosteroid therapy, prednisone dose &gt; 25 mg/d (or&#xD;
             equivalent) or change in prednisone dose within 4 weeks prior to screening;&#xD;
&#xD;
          -  Addition of a new medication, or change in the dose of any background medication used&#xD;
             to treat any aspect of pemphigus within the timeframes listed below. Specifically:&#xD;
&#xD;
               -  methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine,&#xD;
                  cyclosporine or dapsone within the 6 weeks prior to screening or in the time&#xD;
                  between screening and study drug infusion,&#xD;
&#xD;
               -  intravenous Immunoglobulin (IVIG) within 12 weeks prior to screening or in the&#xD;
                  time between screening and study drug infusion (subjects on IVIG must be on&#xD;
                  stable dose for at least 12 weeks prior to screening),&#xD;
&#xD;
               -  treatment with cyclophosphamide within 12 weeks prior to screening or in the time&#xD;
                  between screening and study drug infusion.&#xD;
&#xD;
          -  Doses of background medications at screening:&#xD;
&#xD;
               -  methotrexate &gt; 25 mg/week,&#xD;
&#xD;
               -  mycophenolate mofetil &gt; 3000 mg/d,&#xD;
&#xD;
               -  mycophenolic acid &gt; 1080 mg/bid,&#xD;
&#xD;
               -  azathioprine &gt; 200 mg/d,&#xD;
&#xD;
               -  cyclosporine &gt; 2 mg/kg/d,&#xD;
&#xD;
               -  dapsone &gt;250 mg/d,or&#xD;
&#xD;
               -  intravenous immunoglobulin (IVIG) &gt; 4mg/kg monthly.&#xD;
&#xD;
          -  Use of rituximab within the 12 months prior to screening;&#xD;
&#xD;
          -  Change in dosing frequency, concentration, or applied surface area of topical steroids&#xD;
             and/or topical calcineurin inhibitors within 2 weeks prior to screening;&#xD;
&#xD;
          -  Paraneoplastic pemphigus;&#xD;
&#xD;
          -  Pemphigus erythematosus;&#xD;
&#xD;
          -  Pemphigus vegetans;&#xD;
&#xD;
          -  Immunoglobulin A (IgA) pemphigus;&#xD;
&#xD;
          -  Drug-induced pemphigus;&#xD;
&#xD;
          -  Blood donation within 10 weeks prior to baseline visit (Day 0);&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dL;&#xD;
&#xD;
          -  White blood cell (WBC) count &lt; 3,000/ mm^3 (equivalent to &lt; 3 x10^9/L);&#xD;
&#xD;
          -  Lymphocyte count &lt; 800/mm^3 (equivalent to &lt; 0.8 x10^9/L);&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1,500/mm^3 (equivalent to &lt; 1.5 x10^9/L);&#xD;
&#xD;
          -  Platelets &lt; 100,000/mm^3 (equivalent to &lt; 100 x 10^9/L);&#xD;
&#xD;
          -  Liver function test [aspartate aminotransferase (AST)], alanine aminotransferase&#xD;
             (ALT), or alkaline phosphatase (ALK)] results that are ≥ 2 times the upper limit of&#xD;
             normal (ULN);&#xD;
&#xD;
          -  Direct bilirubin &gt; ULN;&#xD;
&#xD;
          -  End stage renal disease [estimated glomerular filtration rate (eGFR) &lt; 20&#xD;
             ml/min/1.73m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)&#xD;
             equation];&#xD;
&#xD;
          -  At or within three months of screening:&#xD;
&#xD;
               -  a positive QuantiFERON(R)-TB Gold test or positive purified protein derivative&#xD;
                  tuberculin skin test (PPD) [&gt;5mm induration, regardless of Bacille Calmette&#xD;
                  Guerin (BCG) vaccine administration] unless completion of treatment has been&#xD;
                  documented for active Tuberculosis (TB),&#xD;
&#xD;
               -  an indeterminate QuantiFERON (R)-TB Gold test unless followed by a subsequent&#xD;
                  negative PPD or negative QuantiFERON(R)-TB Gold test as well as a consultation&#xD;
                  with and clearance by local infectious disease (ID) department.&#xD;
&#xD;
          -  Recent or ongoing active bacterial, viral, fungal, or opportunistic infections&#xD;
             requiring systemic anti-infective therapy;&#xD;
&#xD;
          -  Evidence of current or prior infection with human immunodeficiency virus (HIV),&#xD;
             hepatitis B [as assessed by HBsAg and anti-hepatitis B core antigen (HBc) Ab] or&#xD;
             hepatitis C [as assessed by anti-Hepatitis C Virus (anti-HCV) Ab];&#xD;
&#xD;
          -  Detectable circulating EBV or Cytomegalovirus (CMV) genomes or active infection;&#xD;
&#xD;
          -  Chronic infection that is currently being treated with suppressive anti-infective&#xD;
             therapy, including but not limited to tuberculosis, pneumocystis, CMV, herpes zoster,&#xD;
             and atypical mycobacteria, with the exception of historical orolabial or localized&#xD;
             cutaneous herpes simplex infections treated with suppressive anti- viral therapy;&#xD;
&#xD;
          -  Receipt of a live-attenuated vaccine within 12 months prior to screening;&#xD;
&#xD;
          -  Concomitant malignancies or a history of malignancy, with the exception of completely&#xD;
             treated basal cell carcinoma of the skin;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Lactating or breastfeeding;&#xD;
&#xD;
          -  Unwilling or unable to use reliable method(s) of contraception:&#xD;
&#xD;
               -  For females of child-bearing potential, from four weeks prior to Day 0 through&#xD;
&#xD;
                  1 year after Treg dosing;&#xD;
&#xD;
               -  For males, from the day of Treg infusion (baseline visit) to three months after&#xD;
                  Treg infusion.&#xD;
&#xD;
          -  Use of an investigational therapeutic medication, or other biologic medications except&#xD;
             rituximab, within the past 90 days, or 5 half-lives prior to screening, whichever is&#xD;
             greater;&#xD;
&#xD;
          -  Concomitant medical condition that places the subject at risk by participating in this&#xD;
             study, including but not limited to:&#xD;
&#xD;
               -  another severe, systemic autoimmune disease or condition (besides pemphigus)&#xD;
                  requiring systemic immunosuppressive therapy (e.g., rheumatoid arthritis,&#xD;
                  Systemic Lupus Erythematosus (SLE), systemic sclerosis, primary Sjogren's&#xD;
                  syndrome, primary vasculitis, psoriasis, multiple sclerosis, ankylosing&#xD;
                  spondylitis, and inflammatory bowel disease), or&#xD;
&#xD;
               -  severe, progressive, or poorly controlled renal, hepatic, hematological,&#xD;
                  gastrointestinal, pulmonary, cardiac, or neurological disease, or&#xD;
&#xD;
               -  history of significant infection or recurrent infection that, in the&#xD;
                  investigator's opinion, places the subject at risk by participating in this&#xD;
                  study, or&#xD;
&#xD;
               -  any other concomitant medical condition that, in the investigator's opinion,&#xD;
                  places the subject at risk by participating in this study.&#xD;
&#xD;
          -  Comorbidities requiring glucocorticoid therapy, including those which have required&#xD;
             three or more courses of systemic glucocorticoids within the previous 12 months;&#xD;
&#xD;
          -  Current or history within the past year of substance abuse; or&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haley Naik, MD,MHSc</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco School of Medicine: Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Haemel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco School of Medicine: Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rosenblum, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco School of Medicine: Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Bluestone, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UCSF School of Medicine: UCSF Diabetes Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wofsy, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco School of Medicine: Department of Dermatology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care: Department of Dermatology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center: Department of Dermatology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center: Department of Dermatology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.autoimmunitycenters.org/</url>
    <description>Autoimmunity Centers of Excellence (ACE) website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous polyclonal regulatory T cell therapy</keyword>
  <keyword>PolyTregs</keyword>
  <keyword>open-label</keyword>
  <keyword>Phase 1 (safety)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 22, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

